A simple and cost-effective approach to fabricate tunable length polymeric microneedle patches for controllable transdermal drug delivery

Chen, Yongli; Xian, Yiwen; Carrier, Andrew; Youden, Brian; Servos, Mark R.; Cui, Shufen; Luan, Tiangang; Lin, Songyi; Zhang, Xu

doi:10.1039/d0ra01382j

Cited by 23 publications

(16 citation statements)

References 52 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Low Costmentioning

confidence: 99%

“…Polymeric MN-based natural polysaccharide is less expensive than silicon MNs or metal MNs [155]. Polymers such as chitosan, chitin, hyaluronic acid, sodium alginate and starch are used for the fabrication of microneedles due to their low cost [155]. Furthermore, the current microneedle manufacturing processes need to be enhanced to achieve largescale production to completely transfer microchip-based microneedles into therapeutic applications.…”

Section: Low Costmentioning

confidence: 99%

See 1 more Smart Citation

Microneedle-Based Natural Polysaccharide for Drug Delivery Systems (DDS): Progress and Challenges

et al. 2022

View full text Add to dashboard Cite

In this focused progress review, the most widely accepted methods of transdermal drug delivery are hypodermic needles, transdermal patches and topical creams. However, microneedles (MNs) (or microneedle arrays) are low-invasive 3D biomedical constructs that bypass the skin barrier and produce systemic and localized pharmacological effects. In the past, biomaterials such as carbohydrates, due to their physicochemical properties, have been extensively used to manufacture microneedles (MNs). Due to their wide range of functional groups, carbohydrates enable the design and development of tunable properties and functionalities. In recent years, numerous microneedle products have emerged on the market, although much research needs to be undertaken to overcome the various challenges before the successful introduction of microneedles into the market. As a result, carbohydrate-based microarrays have a high potential to achieve a future step in sensing, drug delivery, and biologics restitution. In this review, a comprehensive overview of carbohydrates such as hyaluronic acid, chitin, chitosan, chondroitin sulfate, cellulose and starch is discussed systematically. It also discusses the various drug delivery strategies and mechanical properties of biomaterial-based MNs, the progress made so far in the clinical translation of carbohydrate-based MNs, and the promotional opportunities for their commercialization. In conclusion, the article summarizes the future perspectives of carbohydrate-based MNs, which are considered as the new class of topical drug delivery systems.

show abstract

Section: Low Costmentioning

confidence: 99%

Section: Low Costmentioning

confidence: 99%

Microneedle-Based Natural Polysaccharide for Drug Delivery Systems (DDS): Progress and Challenges

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Use of heat or UV light during the procedure can critically affect the loaded drugs. However, it is a simple, reproducible and scalable process and some improvements have been recently reported ( Chen Y. et al, 2020 ). Drawing lithography is a direct patterning process based on viscosity and elastic deformation of polymers in glass transitions, thereby avoiding the need of mask and light irradiation but requiring polymer curing and with limitations when biodegradable materials are intended to be used ( Lee and Jung, 2012 ).…”

Section: Transdermal Drug Deliverymentioning

confidence: 99%

“…The experience gained from the early MEMS applications has tailored their emerging technology for biotechnological developments including water and environmental monitoring, DNA sequencing and drug discovery ( Bashir, 2004 ). Novel drug delivery methods to release a specific dose of a drug with a certain rate, during an adequate period of time in the targeted tissue and facilitating patient self-administration are becoming increasingly necessary ( Orive et al, 2003 ; Geipel et al, 2007 ; Ruggiero et al, 2018 ; Singh et al, 2019 ; Tharkar et al, 2019 ; Chen Y. et al, 2020 ; Deng et al, 2020 ; Hwang et al, 2020 ). In this sense, advanced biomedical technology will comprise implantable MEMS devices of proven biocompatibility ( Voskerician et al, 2003 ), to carefully release drugs into the body from micro-chambers hosted in the device, eliminating the need for injections or needles ( Grayson et al, 2004 ; Vasudev and Bhansali, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

Mendoza

Scilletta

Bellino

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

In recent years, controlled release of drugs has posed numerous challenges with the aim of optimizing parameters such as the release of the suitable quantity of drugs in the right site at the right time with the least invasiveness and the greatest possible automation. Some of the factors that challenge conventional drug release include longterm treatments, narrow therapeutic windows, complex dosing schedules, combined therapies, individual dosing regimens, and labile active substance administration. In this sense, the emergence of micro-devices that combine mechanical and electrical components, so called micro-electro-mechanical systems (MEMS) can offer solutions to these drawbacks. These devices can be fabricated using biocompatible materials, with great uniformity and reproducibility, similar to integrated circuits. They can be aseptically manufactured and hermetically sealed, while having mobile components that enable physical or analytical functions together with electrical components. In this review we present recent advances in the generation of MEMS drug delivery devices, in which various micro and nanometric structures such as contacts, connections, channels, reservoirs, pumps, valves, needles, and/or membranes can be included in their design and manufacture. Implantable single and multiple reservoir-based and transdermalbased MEMS devices are discussed in terms of fundamental mechanisms, fabrication, performance, and drug release applications.

show abstract

“…Bee venom delivering dosages must be conducted repeatedly to enhance the disordered condition over a planned period. Therefore, it may help to develop means to assist patients to take the medication without the hassle of performing self-injections (when the presence of a medical personal is not available) (Schiff et al, 2017 ; Jung & Jin, 2021 ), also produce an economical administrative solution (B. Y. Lee et al, 2015 ; Chen et al, 2020 ) that causes minimal pain. MN delivery system is an emerging area for both the systemic and local delivery of macromolecules and helps generalize the application of medicine (Bariya et al, 2011 ; Tran et al, 2021 ; Zhang et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic improvement provided by microneedle patch in delivering bee venom, a case study in combating scopolamine-induced neurodegeneration in mouse model

Nguyen

Yoo

An³

et al. 2022

Drug Delivery

View full text Add to dashboard Cite

Much research has shown Bee venom to be an effective neuroprotective agent. However, the usual transdermal injection of bee venom poses many pharmacokinetic disadvantages. Here, we compared the administration of bee venom via subcutaneous injection (SC) and via Microneedle patch (MN). Both administrated routes produce significant recovery effects, however: the MN significantly prolongs the bio-significant-and-yet-lower concentration of bee venom in mice bodies. In contrast, SC could produce only a short period of much higher bee venom levels in the blood and brain. We also see that due to the concentration-response-curve of bee venom (represented by melittin): mice bodies do not require much higher bee venom concentration (seen in the SC group) to produce a much more significant neuroprotective effect (than seen in those treated with the MN method). Therefore, a MN could maintain bee venom levels in mice bodies at lower-yet-more-efficient concentrations. This is important, as bee venom can cause more adverse effects and pain sensations, at higher concentrations. For the first time, we confirmed that the pharmacokinetic advantages of MN delivered bee venom also guarantee a holistic neuroprotection effect (which was shown by SC delivered bee venom in previous research). This was proven via the results of the water maze experiments for long-term learning memory assessment and protein analysis of key neuronal regulatory proteins: BDNF, p-CREB, iNOS, and mArhR 1. In conclusion, for situations where we ought to administrate drugs at a more downward amount, such as bee venom, MN can keep the therapeutic concentrations at a lower, yet interestingly, more-efficient level.

show abstract

A simple and cost-effective approach to fabricate tunable length polymeric microneedle patches for controllable transdermal drug delivery

Cited by 23 publications

References 52 publications

Microneedle-Based Natural Polysaccharide for Drug Delivery Systems (DDS): Progress and Challenges

Microneedle-Based Natural Polysaccharide for Drug Delivery Systems (DDS): Progress and Challenges

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

Pharmacokinetic improvement provided by microneedle patch in delivering bee venom, a case study in combating scopolamine-induced neurodegeneration in mouse model

Contact Info

Product

Resources

About